ST. LOUIS, Oct. 28, 2024 (GLOBE NEWSWIRE) — Immunophotonics, Inc. a clinical-stage biotech firm centered on the invention and improvement of novel immune-activating medication, right now introduced that will probably be collaborating in The ThinkEquity Convention on October 30, 2024, on the Mandarin Oriental Lodge in New York. The ThinkEquity Convention gathers institutional buyers, company purchasers, and different business professionals to focus on groundbreaking improvements and monetary methods.
Lu Alleruzzo, CEO will probably be presenting at South Salon II at 12:00 pm ET on October 30th. Immunophotonics may even be holding one-on-one investor conferences all through the day. buyers can register to attend and schedule on-on-one conferences here.
About ThinkEquity
ThinkEquity is a boutique funding financial institution based by professionals who’ve collaborated for over a decade, collectively financing over $50 billion in private and non-private capital raises, restructurings, and mergers and acquisitions. Previous ThinkEquity conferences have featured over 70 firm shows, 700+ attendees, and 500+ one-on-one conferences, offering a priceless platform for corporations and buyers to attach. To register to attend The ThinkEquity Convention, please observe this link.
About Immunophotonics
Immunophotonics, Inc. is a privately owned clinical-stage biotech firm pioneering the sphere of Interventional Immuno-Oncology™. IP-001, which is the primary asset from the corporate’s mental property platform and is at present administered in a number of scientific trials, has the potential to beat the native defenses of the tumor microenvironment to allow a tumor-specific anticancer immune response in stable tumor indications. By combining routine interventions that use vitality to destroy tumors, akin to ablation or radiation, with intratumoral injection of its proprietary immunoadjuvant, IP-001, Immunophotonics goals to set off a systemically energetic most cancers immunotherapy, also called an abscopal impact. The corporate’s world headquarters is in St. Louis, Missouri, USA, and its European headquarters is in Bern, Switzerland.
Public Relations
[email protected]
Market Information and Knowledge dropped at you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
